Oral Abstract: IBCL-249 Mosunetuzumab Monotherapy Is an Effective and Well-Tolerated Treatment Option for Patients With Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Who Have Received ≥2 Prior Lines of Therapy: Pivotal Results From a Phase I/II Study

Clinical Lymphoma Myeloma and Leukemia（2022）

引用 0|浏览9

暂无评分

摘要

Mosunetuzumab induces high CR rates and durable remissions in patients with R/R FL and ≥2 prior therapies. Mosunetuzumab has favorable safety, allowing administration without mandatory hospitalization.

查看译文

关键词

IBCL,mosunetuzumab,bispecific antibody,relapsed/refractory,follicular lymphoma,Phase I/II

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要